Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ)

Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ) — VMCI valuation read

Across 120 indicators, Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ) lands at VMCI 61/100. The Healthcare sector median is 50, so the 11-point above-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on 002275.SZ in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, 002275.SZ trades at 27.0x earnings, 50% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of 1.4x leaves covenant headroom for 002275.SZ on the trailing balance sheet.

002275.SZ rose 1.5% over the trailing 7 days, with a -9.9% read on a 30-day basis.